🇺🇸 PEG-IFN alfa-2a in United States

4 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Congestive Cardiomyopathy — 1 report (25%)
  2. Ejection Fraction Decreased — 1 report (25%)
  3. Hypothyroidism — 1 report (25%)
  4. Pulmonary Congestion — 1 report (25%)

Source database →

PEG-IFN alfa-2a in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PEG-IFN alfa-2a approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for PEG-IFN alfa-2a in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.